GH Research PLC (GHRS)

NASDAQ: GHRS · Real-Time Price · USD

27.01

-1.48 (-5.19%)

Jun 30, 2026, 4:00 PM EDT - Market closed

GH Research Earnings Call Transcripts

Fiscal Year 2025

Status Update
GH001 showed rapid, robust, and sustained efficacy in TRD, with a high remission rate and favorable safety profile. Long-term data indicate durable remission with infrequent treatments and fewer clinic visits compared to current standards.

Read full transcript →

Press release